PubRank

D G Johns

Author PubWeight™ 117.23‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science 1989 2.70
2 Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest 1993 2.27
3 Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol 1987 2.10
4 Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med 1988 2.08
5 Role of NADPH oxidase in the vascular hypertrophic and oxidative stress response to angiotensin II in mice. Circ Res 2001 2.02
6 Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet 1990 2.02
7 Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine. J Exp Med 1989 1.99
8 Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci U S A 1987 1.96
9 Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther 1990 1.87
10 Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A 1989 1.74
11 Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc Natl Acad Sci U S A 1991 1.67
12 Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1987 1.57
13 Initial studies on the cellular pharmacology of 2',3-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 1986 1.56
14 The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3'-azido-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988 1.45
15 Angiotensin receptors: signaling, vascular pathophysiology, and interactions with ceramide. Am J Physiol Heart Circ Physiol 2001 1.41
16 Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 1988 1.38
17 The clinical pharmacology of antineoplastic agents (first of two parts). N Engl J Med 1975 1.35
18 Mechanism of 'bystander effect' killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther 1997 1.33
19 Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem 1988 1.32
20 Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem 1990 1.27
21 The disposition and metabolism of 2',3'-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 1988 1.26
22 Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol Pharmacol 1994 1.24
23 The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides. Mol Pharmacol 1987 1.21
24 Potent and selective anti-HTLV-III/LAV activity of 2',3'-dideoxycytidinene, the 2',3'-unsaturated derivative of 2',3'-dideoxycytidine. Biochem Biophys Res Commun 1986 1.19
25 Purification and properties of cytidine deaminase from normal and leukemic granulocytes. J Clin Invest 1974 1.16
26 Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochem Pharmacol 1973 1.12
27 Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid. Biochem Pharmacol 1972 1.09
28 9-[(2RS)-3-fluoro-2-phosphonylmethoxypropyl] derivatives of purines: a class of highly selective antiretroviral agents in vitro and in vivo. Proc Natl Acad Sci U S A 1991 1.09
29 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976 1.08
30 The clinical pharmacology of antineoplastic agents (second of two parts). N Engl J Med 1975 1.05
31 Human liver aldehyde oxidase: differential inhibition of oxidation of charged and uncharged substrates. J Clin Invest 1967 1.05
32 Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine. Mol Pharmacol 1991 1.03
33 Ejaculatory abnormalities in mice with targeted disruption of the gene for heme oxygenase-2. Nat Med 1998 1.02
34 Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine. Drug Metab Dispos 1993 1.01
35 On the interaction of the electron acceptor 2,6-dichlorophenolindophenol with bovine milk xanthine oxidase. J Biol Chem 1971 1.00
36 Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection. AIDS Res Hum Retroviruses 1990 0.99
37 Stoichiometric inhibition of reduced xanthine oxidase by hydroxypyrazolo [3,4-d]pyrimidines. J Biol Chem 1970 0.99
38 Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol 1982 0.98
39 The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 1982 0.97
40 In vitro inhibition of hepatitis B virus replication by 2',3'-dideoxyguanosine, 2',3'-dideoxyinosine, and 3'-azido-2',3'-dideoxythymidine in 2.2.15 (PR) cells. J Infect Dis 1991 0.97
41 Quantitation of mitochondrial DNA in human lymphoblasts by a competitive polymerase chain reaction method: application to the study of inhibitors of mitochondrial DNA content. Mol Pharmacol 1994 0.96
42 Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells. Biochem Pharmacol 1995 0.95
43 Ongoing and stimulus-evoked activity of sympathetically correlated neurons in the intermediate zone and dorsal horn of acutely spinalized rats. J Neurophysiol 2000 0.94
44 Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci U S A 1995 0.94
45 Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature 1972 0.94
46 Binding of maytansine to rat brain tubulin. Biochem Biophys Res Commun 1976 0.94
47 Characterization of 2',3'-dideoxycytidine diphosphocholine and 2',3'-dideoxycytidine diphosphoethanolamine. Prominent phosphodiester metabolites of the anti-HIV nucleoside 2',3'-dideoxycytidine. Drug Metab Dispos 1993 0.93
48 2',3'-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 1987 0.93
49 Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase. J Med Chem 1985 0.93
50 Cyclopentenylcytosine triphosphate. Formation and inhibition of CTP synthetase. J Biol Chem 1989 0.92
51 Enzymatic assay for quantification of deoxynucleoside triphosphates in human cells exposed to antiretroviral 2',3'-dideoxynucleosides. Anal Biochem 1994 0.92
52 Accumulation of methotrexate diglutamate in human liver during methotrexate therapy. Biochem Pharmacol 1977 0.91
53 Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the antiviral nucleoside 2' ,3'-dideoxyguanosine. Biochem Biophys Res Commun 1990 0.91
54 Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate. Mol Pharmacol 1990 0.91
55 Initial studies on maytansine-induced metaphase arrest in L1210 murine leukemia cells. Biochem Pharmacol 1975 0.91
56 Nitroreductase activity of mammalian liver aldehyde oxidase. J Pharmacol Exp Ther 1973 0.91
57 The identity of rabbit-liver methotrexate oxidase. Biochim Biophys Acta 1965 0.91
58 Potentiation of the anti-HIV activity of zalcitabine and lamivudine by a CTP synthase inhibitor, 3-deazauridine. Nucleosides Nucleotides Nucleic Acids 2000 0.90
59 Secretion of methotrexate into human milk. Am J Obstet Gynecol 1972 0.90
60 Enhancement of the biological activity of cordycepin (3'-deoxyadenosine) by the adenosine deaminase inhibitor 2'-deoxycoformycin. Biochem Pharmacol 1976 0.89
61 Assay of 5-fluorodeoxyuridine 5'-monophosphate deoxyuridine 5'-monophosphate pools following 5-fluorouracil. Cancer Res 1974 0.89
62 P2X1 stimulation promotes thrombin receptor-mediated platelet aggregation. J Thromb Haemost 2006 0.89
63 Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity. Adv Enzyme Regul 1983 0.88
64 Pharmacokinetics of 2',3'-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin Pharmacol Ther 1991 0.87
65 Adenosine deaminase inhibition for immunosuppression. N Engl J Med 1977 0.87
66 In situ cyclopentenyl cytosine infusion for the treatment of experimental brain tumors. Cancer Res 1995 0.86
67 The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin. Cancer Chemother Pharmacol 1980 0.86
68 Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2'-deoxycoformycin. Pharmacology 1977 0.86
69 Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 1992 0.86
70 Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo. Biochem Pharmacol 1982 0.85
71 Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties. Biochem Pharmacol 1983 0.85
72 Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193). Biochem Pharmacol 1982 0.84
73 Urotensin II and renal function in the rat. Kidney Int 2006 0.84
74 The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles. Rev Infect Dis 1990 0.84
75 Folate antagonists. Annu Rev Med 1967 0.83
76 Arabinosyl-5-azacytosine: mechanisms of native and acquired resistance. Cancer Res 1986 0.82
77 Effect of anti-HIV 2'-beta-fluoro-2',3'-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem Pharmacol 1994 0.82
78 Binding of maytansinoids to tubulin. Biochem Pharmacol 1981 0.82
79 Studies on mechanisms of resistance to cytosine arabinoside: problems in the determination of related enzyme activities in leukemic cells. Ann N Y Acad Sci 1975 0.82
80 The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent. Adv Exp Med Biol 1989 0.82
81 Role of the M2 subunit of ribonucleotide reductase in regulation by hydroxyurea of the activity of the anti-HIV-1 agent 2',3'-dideoxyinosine. Biochem Pharmacol 1998 0.82
82 Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells. J Clin Invest 1985 0.82
83 The relative toxicites of methotrexate and aminopterin. Biochem Pharmacol 1966 0.81
84 Use of a herpes thymidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer. Cancer Gene Ther 2000 0.81
85 Adenosine deaminase inhibitors: differential effects on multiple forms of adenosine deaminase. Biochem Biophys Res Commun 1978 0.81
86 Initial studies on the cytotoxic action of maytansine, a novel ansa macrolide. Biochem Pharmacol 1975 0.81
87 Oxidation of 4-hydroxypyrazolo (3,4-d) pyrimidine by xanthine oxidase, the route of electron transfer from substrate to acceptor dyes. Biochem Biophys Res Commun 1968 0.81
88 Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD). Biochem Pharmacol 1986 0.80
89 Symposium on immunosuppressive drugs. Folate antagonists: some biochemical and pharmacological considerations. Fed Proc 1967 0.80
90 Enzymic hydroxylation of 5-fluoropyrimidines by aldehyde oxidase and xanthine oxidase. Biochem Pharmacol 1966 0.80
91 Antiproliferative effects of cyclopentenyl cytosine (NSC 375575) in human glioblastoma cells. Oncol Res 1997 0.80
92 Resistance to cyclopentenylcytosine in murine leukemia L1210 cells. Cancer Res 1993 0.80
93 Tiazofurin: a new antitumor agent. Invest New Drugs 1984 0.79
94 Metabolism in human leukocytes of anti-HIV dideoxypurine nucleosides. Ann N Y Acad Sci 1990 0.79
95 Effects of hycanthone on rapidly proliferating cells. Biochem Pharmacol 1973 0.79
96 Sites of inhibition of DNA synthesis by kethoxal bis(thiosemicarbazone). Nature 1968 0.79
97 Suppression of replication of multidrug-resistant HIV type 1 variants by combinations of thymidylate synthase inhibitors with zidovudine or stavudine. Mol Pharmacol 1999 0.79
98 Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody. AIDS Res Hum Retroviruses 1990 0.79
99 Cellular pharmacology of cyclopentenyl cytosine in Molt-4 lymphoblasts. Cancer Res 1991 0.79
100 2',3'-Dideoxynucleoside phosphorylation by deoxycytidine kinase from normal human thymus extracts: activation of potential drugs for AIDS therapy. Biochem Biophys Res Commun 1987 0.79
101 Spinal interneurons play a minor role in generating ongoing renal sympathetic nerve activity in spinally intact rats. Brain Res 2001 0.79
102 Quinazoline antifolates as inhibitors of dihydrofolate reductase from human leukemia cells. Biochem Pharmacol 1970 0.78
103 Modulation of metabolism and anti-HIV-1 activity of purine 2',3'-dideoxynucleosides by IMP dehydrogenase inhibitors. Adv Exp Med Biol 1991 0.78
104 Preliminary clinical trials of dichloromethotrexate (NSC-29630) in hepatocellular carcinoma. Cancer Chemother Rep 1972 0.78
105 Experimental studies with maytansine--a new antitumor agent. Bibl Haematol 1975 0.78
106 Thiazole-4-carboxamide adenine dinucleotide (TAD). Analogues stable to phosphodiesterase hydrolysis. J Med Chem 1986 0.78
107 Avascular necrosis in HIV infection. AIDS 1999 0.78
108 Studies on the mode of oxidation of pyrazolo(3,4-d)pyrimidine by aldehyde oxidase and xanthine oxidase. Biochem Pharmacol 1969 0.78
109 Enzyme inhibition titration assay for 2'-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats. Biochem Pharmacol 1979 0.78
110 Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin. Biochem Pharmacol 1984 0.78
111 Initial mechanistic studies with merbarone (NSC 336628). Biochem Pharmacol 1985 0.78
112 4-Hydroxypyrazolo (3,4-d) pyrimidine as a substrate for xanthine oxidase: loss of conventional substrate activity with catalytic cycling of the enzyme. Biochem Biophys Res Commun 1970 0.77
113 Synthesis of thiazole-4-carboxamide adenine dinucleotide. A powerful inhibitor of IMP dehydrogenase. J Med Chem 1983 0.77
114 Dose-dependent metabolism of methotrexate in man and rhesus monkeys. Cancer Treat Rep 1977 0.75
115 Comparison of the DNA incorporation in human MOLT-4 cells of two 2'-beta-fluoronucleosides, 2'-beta-fluoro-2',3'-dideoxyadenosine and fialuridine. J Pharm Sci 1996 0.75
116 Letter: Altered plasma pharmacokinetics of methotrexate administered intrathecally. Lancet 1975 0.75
117 Measurement of cyclopentenyl cytosine 5'-triphosphate in vitro and in vivo by multidimensional high-performance liquid chromatography. Anal Biochem 1993 0.75
118 Antineoplastic activity of lipid-soluble dialkyl esters of methotrexate. Experientia 1973 0.75
119 Decay rates of anti-HIV dideoxynucleotides in tissue culture systems: a simple correction for the effect of cell replication. Drug Metab Dispos 1997 0.75
120 Recent advances in the biochemical pharmacology of folic acid antagonists. Transplant Proc 1973 0.75
121 Metabolism of folate antagonists. Ann N Y Acad Sci 1971 0.75
122 Dialkyl esters of methotrexate and 3',5'-dichloromethotrexate: synthesis and interaction with aldehyde oxidase and dihydrofolate reductase. Drug Metab Dispos 1974 0.75
123 Metabolic pathways for the activation of the antiviral agent 2',3'-dideoxyguanosine in human lymphoid cells. Mol Pharmacol 1992 0.75
124 Dihydrofolate reductase from guinea pig liver and small intestine. Biochem Pharmacol 1966 0.75
125 3',5'-ditritiomethotrexate as a granulocyte label. Nature 1965 0.75
126 Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia. Invest New Drugs 1985 0.75
127 Tubulin-dependent biochemical assay for the antineoplastic agent taxol and application to measurement of the drug in serum. Cancer Treat Rep 1982 0.75
128 131-I-3'-iodoaminopterin: a gamma-labeled active-site-directed enzyme inhibitor. J Nucl Med 1968 0.75
129 Aminopterin--iodine-131, a folate antagonist. Preparation, distribution, and scanning in man. J Nucl Med 1967 0.75
130 Biosynthetic ganciclovir triphosphate: its isolation and characterization from ganciclovir-treated herpes simplex thymidine kinase-transduced murine cells. Biochem Biophys Res Commun 2001 0.75
131 Enhancement by 2'-deoxycoformycin of the 5'-phosphorylation and anti-human immunodeficiency virus activity of 2',3'-dideoxyadenosine and 2'-beta-fluoro-2',3'-dideoxyadenosine. Mol Pharmacol 1994 0.75
132 Anomalous differential effects of 4-hydroxypyrazolo (3,4-d)-pyrimidine on electron transfer from xanthine oxidase to molecular oxygen and to acceptor dyes. Biochem Biophys Res Commun 1968 0.75
133 Effects of IMP dehydrogenase inhibitors on the phosphorylation of ganciclovir in MOLT-4 cells before and after herpes simplex virus thymidine kinase gene transduction. Mol Pharmacol 1994 0.75
134 2',3'-Didehydro-3'-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5'-triphosphate biosynthesis. Mol Pharmacol 1996 0.75
135 Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties. Cancer Res 1986 0.75
136 Physiological disposition of 2,6-dimethyl-4-benzyl-4-demethylrifampicin in rats, mice, and dogs. Drug Metab Dispos 1974 0.75
137 Reversal by cytidine of cyclopentenyl cytosine-induced toxicity in mice without compromise of antitumor activity. Biochem Pharmacol 1995 0.75